Correlation Between GlaxoSmithKline PLC and Catalyst/exceed Defined
Can any of the company-specific risk be diversified away by investing in both GlaxoSmithKline PLC and Catalyst/exceed Defined at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GlaxoSmithKline PLC and Catalyst/exceed Defined into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GlaxoSmithKline PLC ADR and Catalystexceed Defined Shield, you can compare the effects of market volatilities on GlaxoSmithKline PLC and Catalyst/exceed Defined and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GlaxoSmithKline PLC with a short position of Catalyst/exceed Defined. Check out your portfolio center. Please also check ongoing floating volatility patterns of GlaxoSmithKline PLC and Catalyst/exceed Defined.
Diversification Opportunities for GlaxoSmithKline PLC and Catalyst/exceed Defined
-0.85 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between GlaxoSmithKline and Catalyst/exceed is -0.85. Overlapping area represents the amount of risk that can be diversified away by holding GlaxoSmithKline PLC ADR and Catalystexceed Defined Shield in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Catalyst/exceed Defined and GlaxoSmithKline PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GlaxoSmithKline PLC ADR are associated (or correlated) with Catalyst/exceed Defined. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Catalyst/exceed Defined has no effect on the direction of GlaxoSmithKline PLC i.e., GlaxoSmithKline PLC and Catalyst/exceed Defined go up and down completely randomly.
Pair Corralation between GlaxoSmithKline PLC and Catalyst/exceed Defined
Considering the 90-day investment horizon GlaxoSmithKline PLC ADR is expected to under-perform the Catalyst/exceed Defined. In addition to that, GlaxoSmithKline PLC is 3.07 times more volatile than Catalystexceed Defined Shield. It trades about -0.23 of its total potential returns per unit of risk. Catalystexceed Defined Shield is currently generating about 0.35 per unit of volatility. If you would invest 1,021 in Catalystexceed Defined Shield on September 1, 2024 and sell it today you would earn a total of 33.00 from holding Catalystexceed Defined Shield or generate 3.23% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Significant |
| Accuracy | 95.45% |
| Values | Daily Returns |
GlaxoSmithKline PLC ADR vs. Catalystexceed Defined Shield
Performance |
| Timeline |
| GlaxoSmithKline PLC ADR |
| Catalyst/exceed Defined |
GlaxoSmithKline PLC and Catalyst/exceed Defined Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with GlaxoSmithKline PLC and Catalyst/exceed Defined
The main advantage of trading using opposite GlaxoSmithKline PLC and Catalyst/exceed Defined positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GlaxoSmithKline PLC position performs unexpectedly, Catalyst/exceed Defined can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst/exceed Defined will offset losses from the drop in Catalyst/exceed Defined's long position.| GlaxoSmithKline PLC vs. Novartis AG ADR | GlaxoSmithKline PLC vs. AstraZeneca PLC ADR | GlaxoSmithKline PLC vs. Roche Holding Ltd | GlaxoSmithKline PLC vs. Bristol Myers Squibb |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Complementary Tools
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |